Holen Sie sich die Stockscreener-App
15.41
3.39%
-0.54
Vorhandelsmarkt:
15.09
-0.32
-2.08%
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application - Insider Monkey
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Is Ocular Therapeutix Inc a good long term investmentAnalyst Downgrades & Big Gains Low Investment - earlytimes.in
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Chardan Capital Maintains Buy Rating on OCUL with $21 Price Targ - GuruFocus
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD - Eyes On Eyecare
Ocular Therapeutix: Not So Fast On The Single-Trial Bet (Rating Downgrade) (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix stock price target raised to $30 by RBC on wAMD trial outlook - Investing.com Canada
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
OCUL Stock Surge: Analysts Weigh In - StocksToTrade
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission By Investing.com - Investing.com Australia
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission - Investing.com
Why Is Ocular Therapeutix Stock Skyrocketing Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
Paramount Skydance, Wave Life Sciences, Ocular… - inkl
Ocular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Needham & Company LLC - MarketBeat
OCUL: Needham Reiterates Buy Rating with $20 Price Target | OCUL Stock News - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year HighHere's Why - MarketBeat
Ocular Therapeutix stock price target raised to $28 from $19 at Raymond James - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD By Investing.com - Investing.com India
Ocular Therapeutix stock hits 52-week high at 14.79 USD - Investing.com
Ocular Therapeutix Inc.’s Breakthrough: Will It Spark a Surge? - timothysykes.com
OCUL's Target Price Raised to $21 by HC Wainwright & Co. | OCUL Stock News - GuruFocus
H.C. Wainwright raises Ocular Therapeutix stock price target to $21 on FDA pathway - Investing.com UK
Ocular Therapeutix says SOL-1 topline data expected in first quarter 2026 - marketscreener.com
Ocular Therapeutix (OCUL) Plans NDA Submission for Wet AMD Treat - GuruFocus
Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug - TradingView
Ocular Therapeutix Plans NDA Submission for AXPAXLI in Wet AMD Following Positive SOL-1 Year One Data - Quiver Quantitative
Ocular Therapeutix, Inc. Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD - marketscreener.com
Ocular Therapeutix, Inc. $OCUL Position Boosted by Pale Fire Capital SE - MarketBeat
Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Ocular Therapeutix plans new drug application for AXPAXLI based on Phase 3 data - Investing.com Nigeria
Ocular Therapeutix Plans NDA Submission for Wet AMD Treatment - TradingView
Ocular Therapeutix (NASDAQ:OCUL) Trading Up 12.3%What's Next? - MarketBeat
With Ocular Therapeutix Stock Surging, Have You Considered The Downside? - Trefis
Ocular Therapeutix reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Saturn V Capital Management LP Purchases 130,385 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
What sentiment indicators say about Ocular Therapeutix Inc. stockWeekly Trade Recap & High Return Trade Opportunity Guides - Newser
How Ocular Therapeutix Inc. stock reacts to inflationary pressuresDollar Strength & Reliable Breakout Forecasts - Newser
How forex fluctuations impact Ocular Therapeutix Inc. (0OT) stockJuly 2025 PostEarnings & Weekly Top Gainers Trade List - Newser
OCUL: Phase III trials target a first-in-class superiority label and durable retinal disease therapy - TradingView
Discipline and Rules-Based Execution in OCUL Response - news.stocktradersdaily.com
Investors Interested In Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Revenues - 富途牛牛
Is Ocular Therapeutix Inc. stock cheap compared to fundamentals2025 Year in Review & Stepwise Trade Signal Guides - Newser
Ocular Therapeutix (OCUL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Geode Capital Management LLC Has $30.48 Million Stake in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Hedge Fund Bets: What is the fair value of Ocular Therapeutix Inc. stock now2025 Sector Review & Smart Swing Trading Alerts - moha.gov.vn
Intech Investment Management LLC Sells 22,361 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Highs Report: Why analysts raise outlook for Ocular Therapeutix Inc. (0OT) stock2025 Volatility Report & Safe Swing Trade Setup Alerts - moha.gov.vn
Ocular Therapeutix CEO Dugel sells $235k in stock By Investing.com - Investing.com Australia
Officer Nayak Surrenders 1,878 Of Ocular Therapeutix Inc [OCUL] - TradingView
Officer Kaiser Surrenders 3,007 Of Ocular Therapeutix Inc [OCUL] - TradingView
Officer Heier Surrenders 3,469 Of Ocular Therapeutix Inc [OCUL] - TradingView
Ocular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from HC Wainwright - MarketBeat
How HELIOS-3 Phase 3 Trial Enrollment at Ocular Therapeutix (OCUL) Has Changed Its Investment Story - Sahm
OCUL: HC Wainwright & Co. Reiterates Buy Rating with $19 Price T - GuruFocus
HC Wainwright & Co. Reiterates Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix Begins Phase 3 Registrational Program to Potentially Treat Non-Proliferative Diabetic Retinopathy - marketscreener.com
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):